Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday, MarketBeat reports. The brokerage currently has a $65.00 price objective on the stock. Vetr‘s target price indicates a potential upside of 20.19% from the company’s previous close.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up 1.08% on Tuesday, hitting $54.08. The company had a trading volume of 7,332,998 shares. The company has a market capitalization of $49.09 billion and a price-to-earnings ratio of 29.71. Teva Pharmaceutical Industries has a 52 week low of $52.62 and a 52 week high of $72.31. The stock’s 50-day moving average is $57.30 and its 200 day moving average is $60.90.
Other equities research analysts also recently issued research reports about the company. Citigroup Inc. dropped their price objective on Teva Pharmaceutical Industries from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, March 9th. Canaccord Genuity dropped their price objective on Teva Pharmaceutical Industries from $72.00 to $68.00 and set a “hold” rating on the stock in a research report on Tuesday, February 16th. Finally, Wells Fargo initiated coverage on Teva Pharmaceutical Industries in a research report on Friday, February 19th. They set an “outperform” rating on the stock.
Source: American Banking and Market News